1. Home
  2. LZB vs ADPT Comparison

LZB vs ADPT Comparison

Compare LZB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LZB
  • ADPT
  • Stock Information
  • Founded
  • LZB 1927
  • ADPT 2009
  • Country
  • LZB United States
  • ADPT United States
  • Employees
  • LZB N/A
  • ADPT N/A
  • Industry
  • LZB Home Furnishings
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LZB Consumer Discretionary
  • ADPT Health Care
  • Exchange
  • LZB Nasdaq
  • ADPT Nasdaq
  • Market Cap
  • LZB 1.6B
  • ADPT 1.8B
  • IPO Year
  • LZB N/A
  • ADPT 2019
  • Fundamental
  • Price
  • LZB $39.35
  • ADPT $11.82
  • Analyst Decision
  • LZB Buy
  • ADPT Strong Buy
  • Analyst Count
  • LZB 2
  • ADPT 7
  • Target Price
  • LZB $46.00
  • ADPT $10.57
  • AVG Volume (30 Days)
  • LZB 589.0K
  • ADPT 2.4M
  • Earning Date
  • LZB 08-19-2025
  • ADPT 07-31-2025
  • Dividend Yield
  • LZB 2.20%
  • ADPT N/A
  • EPS Growth
  • LZB N/A
  • ADPT N/A
  • EPS
  • LZB 2.35
  • ADPT N/A
  • Revenue
  • LZB $2,109,207,000.00
  • ADPT $189,527,000.00
  • Revenue This Year
  • LZB $3.83
  • ADPT $24.46
  • Revenue Next Year
  • LZB $3.88
  • ADPT $20.25
  • P/E Ratio
  • LZB $17.03
  • ADPT N/A
  • Revenue Growth
  • LZB 3.04
  • ADPT 8.61
  • 52 Week Low
  • LZB $35.18
  • ADPT $3.51
  • 52 Week High
  • LZB $48.31
  • ADPT $12.43
  • Technical
  • Relative Strength Index (RSI)
  • LZB 49.67
  • ADPT 63.35
  • Support Level
  • LZB $38.61
  • ADPT $11.41
  • Resistance Level
  • LZB $41.06
  • ADPT $12.36
  • Average True Range (ATR)
  • LZB 1.07
  • ADPT 0.59
  • MACD
  • LZB 0.27
  • ADPT -0.01
  • Stochastic Oscillator
  • LZB 59.29
  • ADPT 72.65

About LZB La-Z-Boy Incorporated

La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: